Skip to content

Beyond Symptom Reduction: Interconnectedness and Self-Transcendent Emotions During MDMA Sessions Predict Flourishing, Not Symptom Change, in Social Anxiety Disorder Treatment

Christina Chwyl, Mary K. Lear, Jason B. Luoma

October 20, 2026 preprint DOI: 10.31234/osf.io/kbxdq_v1 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Secondary analysis of a randomized waitlist-controlled trial
Sample size 20
Population Adults with generalized social anxiety disorder
Duration Two MDMA sessions; outcomes measured at baseline and post-treatment (16 weeks)
Topics Anxiety MDMA
Registration NCT05138068
Key findings Connection-oriented self-transcendent experiences during MDMA-assisted therapy predicted greater post-treatment belonging, gratitude, and purpose in life, but not social anxiety reduction. Self-loss experiences were infrequently endorsed and did not predict outcomes. The authors propose that connection-focused self-transcendent experiences may be important for promoting psychological flourishing and eudaimonic wellbeing.

Abstract

By fostering certain self-transcendent experiences (STE)—those characterized by interconnectedness and other-oriented emotions—3,4-Methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) has been hypothesized to disrupt social anxiety disorder maintenance processes, including negative self-focus, self-criticism, and isolation, thereby enhancing wellbeing. This secondary analysis used data from a randomized waitlist controlled trial of MDMA-AT for generalized social anxiety disorder (N = 20; NCT05138068). It characterized STE during MDMA-AT and examined their relationships with social anxiety symptoms and wellbeing outcomes. Participants reported on STE following two MDMA sessions. Outcomes (social anxiety, gratitude, belonging, purpose in life) were measured at baseline and post-treatment (16 weeks). Paired-samples t-tests examined changes across sessions and pre-to-post treatment, and regression analyses tested whether in-session experiences predicted outcome improvements. Sessions elicited blissful states, and positive and ST emotions, with few negative emotions reported. In-session experiences, especially connection-oriented STE, predicted greater post-treatment belonging, gratitude, and purpose in life, though not social anxiety reduction. STE involving a sense of self-loss were infrequently endorsed and did not predict outcomes. Findings highlight the potential importance of connection-focused STE and emotions during MDMA-AT for promoting psychological flourishing and eudaimonic wellbeing, laying the groundwork for future larger-scale mechanistic trials.

In the evidence

This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.

  • Connection-oriented self-transcendent experiences during MDMA sessions predicted greater post-treatment belonging, gratitude, and purpose in life but did not predict social anxiety reduction.

    Synthesized

Comparable studies

Other randomized controlled trials on MDMA for anxiety, most cited first.

Study Year Design Participants
Gender differences in the subjective effects of MDMA Healthy volunteers with no or minimal MDMA experience 2001 Pooled analysis of three double-blind placebo-controlled studies n = 74
Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Autistic adults with marked to very severe social anxiety 2018 Randomized controlled trial n = 12
MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study People with life-threatening illnesses and anxiety 2020 Randomized controlled trial n = 18
A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults Healthy adults aged 21–55 from a major metropolitan area 2022 Randomized controlled trial n = 34
Effects of MDMA-assisted therapy for PTSD on self-experience Participants with severe PTSD 2024 Randomized controlled trial n = 90

Explore topics

By condition and practice